DESMOPRESSIN ( DrugBank: Desmopressin )


5 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病2
64血栓性血小板減少性紫斑病1
72下垂体性ADH分泌異常症1
225先天性腎性尿崩症1
288自己免疫性後天性凝固因子欠乏症6

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00806468
(ClinicalTrials.gov)
February 20099/12/2008Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson DiseaseA Double Blind, Placebo Controlled, Randomized, Monocentre Cross-over Study to Investigate the Effect of Desmopressin on the Nocturnal Micturition Frequency in Patients With Parkinson DiseaseParkinson DiseaseDrug: DesmotabsJohannes Gutenberg University MainzNULLTerminated18 Years85 YearsMale1Phase 4Germany
2EUCTR2008-003966-25-DE
(EUCTR)
23/12/200804/11/2008Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo. - DEPOPADouble-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo. - DEPOPA Effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome
MedDRA version: 9.1;Level: LLT;Classification code 10064016;Term: Nocturnal polyuria
MedDRA version: 9.1;Classification code 10061536;Term: Parkinson's disease
Trade Name: Desmotabs® 0,2 mg Tabletten
Product Name: Desmotabs® 0,2mg Tabletten
INN or Proposed INN: Desmopressin Acetat
Universität Mainz, Klinik und Poliklinik für NeurologieNULLNot RecruitingFemale: no
Male: yes
20Germany

64. 血栓性血小板減少性紫斑病


臨床試験数 : 92 薬物数 : 85 - (DrugBank : 21) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 76
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-004371-19-AT
(EUCTR)
20/11/200712/12/2007A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients with von Willebrand Factor-Related Platelet Function DisordersA Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients with von Willebrand Factor-Related Platelet Function Disorders von Willebrand Factor- related platelet function disorders : thrombotic thrombocytopenic purpura(TTP) in remission, acute TTP, and von Willebrand Disease Type- 2b (vWD-2b).
MedDRA version: 9.1;Level: LLT;Classification code 10037563;Term: Purpura thrombopenic thrombotic
MedDRA version: 9.1;Classification code 10047715;Term: Von Willebrand's disease
Product Name: ARC1779 Injection
Product Code: ARC1779
Other descriptive name: ARC 1779
Trade Name: Octostim
Product Name: desmopressin acetate
Product Code: desmopressin acetate
INN or Proposed INN: desmopressin acetate
Trade Name: Minirin
Product Name: desmopressin
Product Code: desmopressin
INN or Proposed INN: desmopressin acetate
Product Name: ARC1779 Injection
Product Code: ARC1779
Other descriptive name: ARC 1779
Archemix Corp.NULLNot RecruitingFemale: yes
Male: yes
28Phase 2Austria

72. 下垂体性ADH分泌異常症


臨床試験数 : 41 薬物数 : 27 - (DrugBank : 8) / 標的遺伝子数 : 7 - 標的パスウェイ数 : 10
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01280188
(ClinicalTrials.gov)
January 201119/1/2011A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).Peroral Administration of Different Doses of Desmopressin Administered as a New Orally-Disintegrating Tablet and Desmopressin for Nasal Administration in the Treatment of CDI in Japanese PatientsCentral Diabetes InsipidusDrug: Desmopressin Oral Melt;Drug: Desmopressin intranasalFerring PharmaceuticalsNULLCompleted6 Years75 YearsBoth20Phase 3Japan

225. 先天性腎性尿崩症


臨床試験数 : 15 薬物数 : 48 - (DrugBank : 18) / 標的遺伝子数 : 31 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-001809-24-NL
(EUCTR)
31/07/201306/09/2012A diminished concentrating ability of the kidneys due to lithium prescription: how many and whom is affected?Evaluation of urinary concentrating defects in lithium treated patients with a dDAVP test - Nephrogenic diabetes insipidus (NDI) in lithium treated patients lithium-induced urinary concentrating defects (nephrogenic diabetes insipidus)
MedDRA version: 15.0;Level: LLT;Classification code 10050501;Term: Lithium toxicity;System Organ Class: 10022117 - Injury, poisoning and procedural complications
MedDRA version: 15.0;Classification code 10012600;Term: Diabetes insipidus nephrogenic;System Organ Class: 10038359 - Renal and urinary disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses
Product Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses
Product Code: SUB21605
INN or Proposed INN: desmopressin acetate trihydrate
Other descriptive name: DESMOPRESSIN ACETATE TRIHYDRATE
Radboud University Nijmegen Medical CentreNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Netherlands

288. 自己免疫性後天性凝固因子欠乏症


臨床試験数 : 206 薬物数 : 231 - (DrugBank : 28) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 21
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-001631-46-NL
(EUCTR)
14/02/201913/02/2019Effects of pharmacokinetic models in dosing of DDAVP and/or von Willebrand factor-containing concentrates in patients with von Willebrand diseaseImplementation of pharmacokinetic-guided dosing of DDAVP and VWF-containing concentrates in von Willebrand disease - OPTI-CLOT: To WiN Von Willebrand disease
MedDRA version: 20.0;Level: LLT;Classification code 10055168;Term: Von Willebrand's factor deficiency;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Minrin
INN or Proposed INN: DESMOPRESSIN
Trade Name: Octostim
INN or Proposed INN: DESMOPRESSIN
Trade Name: Octostim
INN or Proposed INN: DESMOPRESSIN
Trade Name: Haemate P
INN or Proposed INN: HUMAN VON WILLEBRAND FACTOR
Other descriptive name: HUMAN VON WILLEBRAND FACTOR
INN or Proposed INN: HUMAN COAGULATION FACTOR VIII
Other descriptive name: HUMAN COAGULATION FACTOR VIII
Trade Name: Wilate
INN or Proposed INN: HUMAN COAGULATION FACTOR VIII
Other descriptive name: HUMAN COAGULATION FACTOR VIII
INN or Proposed INN: HUMAN VON WILLEBRAND FACTOR
Other descriptive name: HUMAN VON WILLEBRAND FACTOR
Trade Name: Wilfactin
INN or Proposed INN: HUMAN VON WILLEBRAND FACTOR
Other descriptive name: HUMAN VON WILLEBRAND FACTOR
Trade Name: Veyvondi
INN or Proposed INN: VON WILLEBRAND FACTOR
Other descriptive name: VON WILLEBRAND FACTOR
Erasmus University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
120Phase 4Netherlands
2EUCTR2009-017060-17-NL
(EUCTR)
10/12/200905/11/2009STIMULATE study: Statins influence on Minrin upregulation of von Willebrand factor and factor VIII - STIMULATESTIMULATE study: Statins influence on Minrin upregulation of von Willebrand factor and factor VIII - STIMULATE Type 1 von Willebrand disease and mild hemophilia ATrade Name: simvastatine
Product Name: simvastatin
INN or Proposed INN: SIMVASTATIN
Trade Name: Minrin
Product Name: Desmopressine
INN or Proposed INN: DESMOPRESSIN
Academic Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
Netherlands
3NCT01994330
(ClinicalTrials.gov)
June 200914/11/2013Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement SurgerySevere Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement SurgeryAcquired Von Willebrand Disease Secondary to Severe Aortic Stenosis;Heye´s Syndrome;Severe Aortic StenosisDrug: desmopressinPontificia Universidad Catolica de ChileFerring PharmaceuticalsCompletedN/AN/AAll13Phase 4Chile
4EUCTR2007-004371-19-AT
(EUCTR)
20/11/200712/12/2007A Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients with von Willebrand Factor-Related Platelet Function DisordersA Phase 2 Pilot Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ARC1779 Injection in Patients with von Willebrand Factor-Related Platelet Function Disorders von Willebrand Factor- related platelet function disorders : thrombotic thrombocytopenic purpura(TTP) in remission, acute TTP, and von Willebrand Disease Type- 2b (vWD-2b).
MedDRA version: 9.1;Level: LLT;Classification code 10037563;Term: Purpura thrombopenic thrombotic
MedDRA version: 9.1;Classification code 10047715;Term: Von Willebrand's disease
Product Name: ARC1779 Injection
Product Code: ARC1779
Other descriptive name: ARC 1779
Trade Name: Octostim
Product Name: desmopressin acetate
Product Code: desmopressin acetate
INN or Proposed INN: desmopressin acetate
Trade Name: Minirin
Product Name: desmopressin
Product Code: desmopressin
INN or Proposed INN: desmopressin acetate
Product Name: ARC1779 Injection
Product Code: ARC1779
Other descriptive name: ARC 1779
Archemix Corp.NULLNot RecruitingFemale: yes
Male: yes
28Phase 2Austria
5EUCTR2005-004496-38-DK
(EUCTR)
22/06/200609/05/2006Desmopressin in the management of von Willebrand disease; Biological versus clinical efficacy.Desmopressin in the management of von Willebrand disease; Biological versus clinical efficacy. von Willebrand disease (VWD) is an inherited bleeding disorder, characterised mainly by mucosal bleedings, which may be life-threatening, and joint bleeds in severe VWD cases. VWD is caused by a lack of von Willebrand factor (VWF) and coagulation factor VIII (FVIII). Treatment of VWD aims at normalizing the VWF activity in plasma, which can be achieved by stimulating the endogenous release of VWF with desmopressin (DDAVP, 1-desamino-8-D arginine vasopressin) or by infusion of a VWF concentrate.Trade Name: Octostim
Product Name: Octostim
Product Code: DDAVP (Desmopressin)
Trade Name: Octostim
Product Name: Octostim
Product Code: DDAVP (Desmopressin)
Rigshospitalet, CopenhagenNULLNot RecruitingFemale: yes
Male: yes
150Phase 4Denmark
6NCT00111215
(ClinicalTrials.gov)
January 200118/5/2005Treatment and Management of Women With Bleeding DisordersTreatment and Management of Women With Bleeding DisordersMenorrhagia;Blood Coagulation Disorders;Blood Platelet Disorders;Von Willebrand Disease;Hematologic DiseaseDrug: Tranexamic Acid;Drug: Desmopressin AcetateCenters for Disease Control and PreventionNULLCompleted18 Years50 YearsFemale100N/AUnited States